In 2020, a global outbreak of the new crown epidemic disrupted the business activities of almost all companies, and the drug R&D and production of pharmaceutical companies is no exception.
As a CRO/CDMO company serving pharmaceutical companies, its market share and global ranking have also changed when the global market order is chaotic.
2021 global CRO ranking TOP10
Note: ①This list covers CRO in a broad sense, and its business areas cover preclinical research, clinical trials, pharmaceutical development, and commissioned production of raw materials and drugs (CDMO and CMO) related to new drug research and development; ②The two data of ICON+PRA are directly related Plus; ③Lonza's income is 4.
5 billion Swiss francs, and the exchange rate is converted into US dollars at 1.
1; ④Catalent's fiscal year is from July 2019 to June 2020; ⑤Wuxi includes Wuxi AppTec and WuXi Biologics, and the combined income is converted to US dollars at an exchange rate of 6.
8; ⑥Parexel has been delisted after being acquired by a consortium in 2017.
Only the income announced in 2018 is here for reference.
Judging from the TOP10 list, the top two CRO companies in the world both have revenues of more than US$10 billion, widening a huge gap with the players behind them, and their dominant position is unbreakable.
ICON’s acquisition of PRA has become a major event in the industry, which has greatly improved the ranking of the new company’s business scale, making it the third largest company in the world.
Syneos is the only company on the list that has shrunk in performance (Parexel is not known), while WuXi is the only Chinese element in the list.
Its growth rate is far ahead and its ranking is steadily rising.
Mainly because under the new crown virus epidemic, China was the first to restore order to resume work and production, and a large number of orders were transferred to China.
Charles River, which once gave up the acquisition of WuXi, is now surpassed by WuXi.
Also benefiting from the new crown virus epidemic are Labcorp and Catalent's testing business and vaccine production business, respectively.
Companies with a larger proportion of clinical research businesses are more affected by the epidemic, but generally recover in the fourth quarter of 2020.
This article gives a brief introduction to the world's TOP10 CRO companies.
The main business of LabCorp is clinical diagnostics.
After successive acquisitions of Covance and Chiltern, it has fully entered the field of drug research and development, whether it is preclinical research or clinical research.
One of the global leaders.
After these two big mergers and acquisitions, the company has become the world's largest CRO.
In 2020, the company's revenue is approaching US$14 billion, an increase of 21% over the previous year.
Affected by the new crown virus epidemic, most industries and companies around the world are facing varying degrees of impact, but it is very good for the company's diagnostic business.
The new crown virus detection business contributed as much as 24.
1% to the full-year performance of 2020.
The company has a large and complete laboratory system not only in North America, but also in the world.
In 2020, the total number of global employees will reach 75,000.
2 IQVIA (Ai Kunwei)
Although in terms of performance and size, IQVIA is slightly lower than Labcorp, but the industry generally believes that IQVIA has a greater influence than Labcorp, and this has to mention the company's predecessor.
In 2016, Quintiles and IMS Health merged to form IQVIA, which became the most important event in the industry that year.
These two companies are the leaders and the gold standard in their respective subdivisions.
Such a strong combination will inevitably lead to a giant, but because Labcorp has entered the field of drug research and development in about the same time, it has to be resigned.
However, in the subdivision field, each has its own unique advantages.
In 2020, the company's revenue was 11.
36 billion U.
dollars, an increase of only 2.
% compared to the previous year.
The main reason was that clinical research was affected by the new crown virus and the progress was slow, especially in North America.
Fortunately, in the fourth quarter, various businesses have clearly recovered, and it can be predicted that the growth in 2021 will be better than that in 2020.
In 2020, IQVIA has 70,000 employees worldwide.
PRA’s revenue in 2020 was US$3.
183 billion, an increase of 3.
8% over the previous year; while ICON’s revenue in 2020 was US$2.
797 billion, a decrease of 0.
3% over the previous year.
The two companies have 19,000 and 16,000 employees respectively.
In February 2021, ICON announced the acquisition of PRA for US$12 billion.
The new company will achieve growth of more than 10% in the first year, and will grow by more than 20% in the future.
These two were originally in the global TOP10.
Relatively speaking, ICON is slightly smaller than PRA, but this does not prevent ICON from acquiring PRA in a way that small fish eat big fish.
After the merger, the new company came to the third place in the world in one fell swoop.
4 Lonza (Lonza)
Lonza is undisputedly the world's largest CDMO company.
The Lonza Group operates two major businesses, of which the Lonza Special Ingredients Business (LSI) focuses on the microbiological control of personal care products, and the volume within the group is relatively small.
The pharmaceutical and biotechnology and nutrition business (LPBN) is Lonza's main source of income, covering from early discovery, customized development to the production of active pharmaceutical ingredients and innovative dosage forms, and is a well-known CDMO business in the industry.
In 2020, the company's revenue was 4.
5 billion Swiss francs, achieving 12.
The company also decided to divest the relatively small special component business and make structural adjustments to make the business more focused and improve transparency, productivity and operational efficiency.
In response to the new coronavirus epidemic, Lonza used global production capacity to provide a full range of development and production services for Moderna's new coronavirus RNA vaccine (mRNA-1273), with an estimated annual production capacity of 1 billion doses.
PPD, founded in 1985 by Fred Eshelman, Ph.
, had its first IPO in 1996.
In 2011, the company was privatized with a US$3.
9 billion acquisition.
It will be listed again on Nasdaq in the United States in 2020.
It has to be said that PPD has made great moves in China, including the completion of two mergers and acquisitions in China in 2009, the acquisition of Igus and Baonuo, which were of considerable scale in China at that time.
Among them, Baonuo founder John V.
Oyler founded BeiGene in 2010.
PPD's 2020 revenue is 4.
68 billion U.
dollars, achieving 16.
6 Syneos Health
In 2017, INC Research and Inventiv Health merged to form Syneos Health, which once climbed to the third position in the world.
In 2020, the company's revenue was 4.
42 billion U.
It is the only company on the list that has suffered negative growth in performance due to the impact of the new crown virus epidemic, and its ranking has also declined.
Although WuXi Biologics and WuXi PharmaTech are two independently-operated listed companies, considering that WuXi Biologics originated from WuXi PharmaTech and the chairman of the two companies is the same person, the two companies are referred to as WuXi PharmaTech.
Department of consolidated calculations.
WuXi's business covers all aspects of new drug research and development, almost all-encompassing and omnipotent, and is already a global giant.
Although it has not yet become the global leader, the influence that everyone feels is undoubtedly insurmountable by its peers.
In 2020, WuXi's consolidated revenue was approximately US$3.
26 billion, an increase of 31.
4% over 2019.
The number of employees reached 32,000.
Regardless of income or personnel, the growth rate is far ahead of its peers.
And judging from the development trend in recent years, it will still maintain rapid growth.
The negative impact of the new crown virus epidemic on the company is small in scope, mild in severity and short in time.
On the contrary, the epidemic has played a major role in promoting performance to some extent.
On the one hand, the company has undertaken a number of new coronavirus-related R&D and production projects.
On the other hand, the raging overseas epidemic has caused some orders to be transferred to China.